Viking Therapeutics, Inc. Operating Cash Flow
Viking Therapeutics, Inc. (VKTX) reported Operating Cash Flow of -$239.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-29
- Viking Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$125.17M.
- Viking Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$113.98M.
- Viking Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$85.29M.
- Viking Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$94.00M.
- Viking Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$278.69M.
- Viking Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$87.79M.
- Viking Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$73.38M.
- Viking Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$48.40M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$125.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$239.15M 10-Q · filed 2026-07-29 | -$324.44M derived: sum of 3 quarters · filed 2026-07-29 | -$418.44M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$113.98M 10-Q · filed 2026-04-30 | -$199.27M derived: sum of 2 quarters · filed 2026-04-30 | -$293.27M derived: sum of 3 quarters · filed 2026-04-30 | -$340.33M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$85.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$179.29M derived: sum of 2 quarters · filed 2026-02-11 | -$226.35M derived: sum of 3 quarters · filed 2026-07-29 | -$278.69M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$94.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | -$141.06M derived: sum of 2 quarters · filed 2026-07-29 | -$193.40M 10-Q · filed 2025-10-23 | -$224.58M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$47.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$99.39M 10-Q · filed 2026-07-29 | -$130.57M derived: sum of 3 quarters · filed 2026-07-29 | -$152.53M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$52.33M 10-Q · filed 2026-04-30 | -$83.51M derived: sum of 2 quarters · filed 2026-04-30 | -$105.47M derived: sum of 3 quarters · filed 2026-04-30 | -$133.99M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$31.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$53.14M derived: sum of 2 quarters · filed 2026-02-11 | -$81.66M derived: sum of 3 quarters · filed 2026-02-11 | -$87.79M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$21.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | -$50.48M derived: sum of 2 quarters · filed 2025-10-23 | -$56.61M 10-Q · filed 2025-10-23 | -$74.25M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | -$28.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-23 | -$34.65M 10-Q · filed 2025-07-23 | -$52.29M derived: sum of 3 quarters · filed 2026-02-11 | -$71.94M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$6.13M 10-Q · filed 2025-04-24 | -$23.77M derived: sum of 2 quarters · filed 2026-02-11 | -$43.43M derived: sum of 3 quarters · filed 2026-02-11 | -$54.87M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$17.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$37.30M derived: sum of 2 quarters · filed 2026-02-11 | -$48.73M derived: sum of 3 quarters · filed 2026-02-11 | -$73.38M 10-K · filed 2026-02-11 |
| 2023-09-30 | -$19.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-23 | -$31.09M derived: sum of 2 quarters · filed 2024-10-23 | -$55.74M 10-Q · filed 2024-10-23 | -$66.66M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$11.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | -$36.08M 10-Q · filed 2024-07-24 | -$47.00M derived: sum of 3 quarters · filed 2025-02-26 | -$60.50M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$24.64M 10-Q · filed 2024-04-25 | -$35.57M derived: sum of 2 quarters · filed 2025-02-26 | -$49.07M derived: sum of 3 quarters · filed 2025-02-26 | -$62.51M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$10.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$24.43M derived: sum of 2 quarters · filed 2025-02-26 | -$37.87M derived: sum of 3 quarters · filed 2025-02-26 | -$48.40M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$13.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | -$26.94M derived: sum of 2 quarters · filed 2023-10-25 | -$37.47M 10-Q · filed 2023-10-25 | -$49.82M derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | -$13.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | -$23.97M 10-Q · filed 2023-07-26 | -$36.32M derived: sum of 3 quarters · filed 2024-02-07 | -$47.25M derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | -$10.53M 10-Q · filed 2023-04-26 | -$22.88M derived: sum of 2 quarters · filed 2024-02-07 | -$33.81M derived: sum of 3 quarters · filed 2024-02-07 | -$47.24M derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | -$12.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | -$23.28M derived: sum of 2 quarters · filed 2024-02-07 | -$36.71M derived: sum of 3 quarters · filed 2024-02-07 | -$47.59M 10-K · filed 2024-02-07 |
| 2021-09-30 | -$10.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | -$24.36M derived: sum of 2 quarters · filed 2022-10-26 | -$35.24M 10-Q · filed 2022-10-26 | -$40.72M derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | -$13.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | -$24.31M 10-Q · filed 2022-07-27 | -$29.80M derived: sum of 3 quarters · filed 2022-07-27 | -$35.12M derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | -$10.88M 10-Q · filed 2022-04-27 | -$16.36M derived: sum of 2 quarters · filed 2022-04-27 | -$21.68M derived: sum of 3 quarters · filed 2022-04-27 | -$28.35M derived: sum of 4 quarters · filed 2022-04-27 |
| 2020-12-31 | -$5.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | -$10.81M derived: sum of 2 quarters · filed 2022-02-09 | -$17.48M derived: sum of 3 quarters · filed 2022-02-09 | -$21.78M 10-K · filed 2022-02-09 |
| 2020-09-30 | -$5.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$11.99M derived: sum of 2 quarters · filed 2021-11-03 | -$16.29M 10-Q · filed 2021-11-03 | -$28.03M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$6.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | -$10.97M 10-Q · filed 2021-07-28 | -$22.71M derived: sum of 3 quarters · filed 2021-07-28 | -$26.11M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | -$4.30M 10-Q · filed 2021-04-28 | -$16.05M derived: sum of 2 quarters · filed 2021-04-28 | -$19.44M derived: sum of 3 quarters · filed 2021-04-28 | -$25.90M derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | -$11.74M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$15.14M derived: sum of 2 quarters · filed 2021-02-17 | -$21.60M derived: sum of 3 quarters · filed 2021-02-17 | -$24.75M 10-K · filed 2021-02-17 |
| 2019-09-30 | -$3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | -$9.86M derived: sum of 2 quarters · filed 2020-10-28 | -$13.01M 10-Q · filed 2020-10-28 | -$15.69M derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | -$6.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | -$9.61M 10-Q · filed 2020-07-29 | -$12.29M derived: sum of 3 quarters · filed 2020-07-29 | -$17.79M derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | -$3.15M 10-Q · filed 2020-04-30 | -$5.83M derived: sum of 2 quarters · filed 2020-04-30 | -$11.33M derived: sum of 3 quarters · filed 2020-04-30 | -$16.60M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | -$2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$8.18M derived: sum of 2 quarters · filed 2020-02-26 | -$13.45M derived: sum of 3 quarters · filed 2020-02-26 | -$18.75M 10-K · filed 2020-02-26 |
| 2018-09-30 | -$5.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$10.77M derived: sum of 2 quarters · filed 2019-11-05 | -$16.08M 10-Q · filed 2019-11-05 | -$20.02M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | -$5.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$10.57M 10-Q · filed 2019-08-01 | -$14.52M derived: sum of 3 quarters · filed 2019-08-01 | -$17.85M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | -$5.30M 10-Q · filed 2019-05-02 | -$9.25M derived: sum of 2 quarters · filed 2019-05-02 | -$12.58M derived: sum of 3 quarters · filed 2019-05-02 | |
| 2017-12-31 | -$3.95M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$7.28M derived: sum of 2 quarters · filed 2019-03-13 | -$14.76M 10-K · filed 2019-03-13 | |
| 2017-09-30 | -$3.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$10.81M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$7.48M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |